Ganoderma lucidum (Lingzhi) is a Traditional Chinese Medicine which is widely used as a means
to 'strengthen immunity' among patients with cancers. However, there is no published
randomized controlled clinical trial on its efficacy and safety despite the many in vitro
studies on its anti-viral, anti-oxidative, anti-tumour, radioprotective, hepato-protective
and immunomodulatory effects. This study was a randomized, double-blind, placebo-controlled,
parallel clinical trial that investigated the benefits and safety of Ganoderma lucidum
(Lingzhi) in treating children with cancers. Patients were randomized to receive identical
capsules of either Lingzhi or placebo for six months. The primary outcome was the general
Paediatric Quality of Life score. Secondary outcomes included immune functions,
infection-related morbidities, complete blood counts and serum biochemistry, and overall and
event-free survival.
Phase:
Phase 3
Details
Lead Sponsor:
Chinese University of Hong Kong
Collaborators:
Prince of Wales Hospital, Shatin, Hong Kong Princess Margaret Hospital, Hong Kong Queen Elizabeth Hospital, Hong Kong